Not all TMS devices are created equal
The first FDA approval of TMS was in 2008 by Neuronetics (the company that manufactures the Neurostar device). In recent years there have been many other companies making TMS devices; the total is now over 10! The different TMS devices and companies publish different outcome rates, which is important to consider when you’re considering spending time, effort, and money on TMS treatments.
1. NeuroStar (Neuronetics)
- Reported Outcomes: NeuroStar reports an 83% response rate and a 62% remission rate based on clinician ratings. Patient-rated scales show a 69% response rate and a 36% remission rate[1].
2. BrainsWay
- Reported Outcomes: BrainsWay’s Deep TMS has shown an 80% response rate and a 51% remission rate in real-world post-marketing data[2].
3. Magstim
- Reported Outcomes: Magstim reports significant reductions in depression severity, with studies showing a 50% response rate and a 30% remission rate[3].
4. MagVenture
- Reported Outcomes: MagVenture reports a 50% response rate and a 33% remission rate in clinical trials[4].
5. Nexstim
- Reported Outcomes: Nexstim’s SmartFocus® rTMS treatment has shown a 76.2% response rate and a 49.6% remission rate in their patient registry[5].
6. Apollo TMS
Reported Outcomes: Apollo TMS Therapy reports a 50% response rate and a 33% remission rate in clinical trials[6].
References
[2] BrainsWay Announces Publication of Study Data on Accelerated Deep …
[3] TMS for MDD Major Depressive Disorder – Magstim
[4] MagVenture TMS Efficacy – North Country Behavioral Medicine
[5] Nexstim – Nexstim Reports Excellent Treatment Outcomes of Over 400 MDD …